Biogen submitted its application for approval of Alzheimer’s treatment aducanumab in early July. And it’s still targeting a coronavirus treatment with Vir. Is Biogen stock a buy now?

The post Alzheimer's Treatment Fast-Tracked By FDA — Is Biogen Stock A Buy? appeared first on Investor's Business Daily.